ILiAD Biotechnologies Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $4.3M
Latest Deal Amount
  • Investors
  • 6

ILiAD Biotechnologies General Information

Description

Developer of a medical vaccine intended to prevent and offer treatment of human disease caused by Bordetella pertussis. The company's vaccine is a live attenuated pertussis vaccine inducing the immune system to produce protective antibodies against B. pertussis infection, enabling patients to recover from whooping cough and other serious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 4581 Weston Road
  • Suite 260
  • Weston, FL 33331
  • United States
+1 (917) 000-0000

ILiAD Biotechnologies Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ILiAD Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 30-Mar-2020 $4.3M 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC 19-Dec-2018 000.00 000.00 Completed Clinical Trials - Phase 2
5. Angel (individual) 07-Feb-2018 00000 000.00 Completed Clinical Trials - Phase 1
4. Angel (individual) 13-Apr-2017 000 000.00 Completed Clinical Trials - Phase 1
3. Angel (individual) 13-Nov-2015 00000 00.000 Completed Clinical Trials - Phase 1
2. Grant $11.1M $3.81M Completed Clinical Trials - Phase 1
1. Angel (individual) $3.81M $3.81M Completed Clinical Trials - Phase 1
To view ILiAD Biotechnologies’s complete valuation and funding history, request access »

ILiAD Biotechnologies Executive Team (4)

Name Title Board Seat Contact Info
Keith Rubin MD Founder, Chief Executive Officer & Board Member
Walter Greenblatt Chief Financial Officer
Ken Solovay Chief Operating Officer
Cheryl Keech Ph.D Chief Medical Officer & Executive Vice President, Clinical Research
To view ILiAD Biotechnologies’s complete executive team members history, request access »

ILiAD Biotechnologies Board Members (6)

Name Representing Role Since
Ariel Pablos-Mendez MD ILiAD Biotechnologies Board Member 000 0000
Bin Yan Ph.D ILiAD Biotechnologies Board Member 000 0000
Corey Horowitz Network-1 Technologies Board Member 000 0000
Cuong Do ILiAD Biotechnologies Board Member 000 0000
Eric Edidin Self Board Observer 000 0000
You’re viewing 5 of 6 board members. Get the full list »

ILiAD Biotechnologies Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Endo Investors Venture Capital Minority 000 0000 000000 0
JEMS venture capital Venture Capital Minority 000 0000 000000 0
Network-1 Technologies Corporation Minority 000 0000 000000 0
SDS Capital Hedge Fund Minority 000 0000 000000 0
Seedlings Life Science Ventures Corporation Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »